[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Dalla Valle R, Mancini C, Crafa P, Passalacqua R: Pancreatic carcinoma recurrence in the remnant pancreas after a pancreaticoduodenectomy. JOP; 2006;7(5):473-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: We report a rare case of a repeated pancreatic resection in the remnant distal pancreas 18 months after a Whipple R0 procedure.
  • CASE REPORT: In September 2003, a 63-year-old man underwent a Whipple procedure with an extended lymphadenectomy, portal vein resection and direct reconstruction for pancreatic cancer.
  • There were no findings of invasion into the surrounding tissue or distant metastasis.
  • After three months of systemic chemotherapy and a radiological reevaluation (PET and CT) in March 2005, we removed the remnant pancreas.
  • Histopathologically, the tumor was classified as a ductal adenocarcinoma like the tumor which had been removed during the first operation, with infiltration of peripancreatic adipose tissue and a segmentary tract of the transverse mesocolon, without lymph node metastasis.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / surgery. Neoplasm Recurrence, Local / pathology. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16998244.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


2. Aristei C, Amichetti M, Ciocca M, Nardone L, Bertoni F, Vidali C, Italian Society of Radiation Oncology: Radiotherapy in Italy after conservative treatment of early breast cancer. A survey by the Italian Society of Radiation Oncology (AIRO). Tumori; 2008 May-Jun;94(3):333-41
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy in Italy after conservative treatment of early breast cancer. A survey by the Italian Society of Radiation Oncology (AIRO).
  • All centers routinely performed axillary dissection; 45 carried out sentinel node biopsy followed by axillary dissection when the sentinel node was positive.
  • The median interval between surgery and radiotherapy, when chemotherapy was not administered, was 60 days.
  • Adjuvant chemotherapy was preferably administered before radiotherapy.
  • Regional lymph nodes were never irradiated in 10 centers; in all others irradiation depended on the number of positive lymph nodes and/or involvement of axillary fat and/or tumor location in medial quadrants.
  • In 59 centers the boost dose of 10 Gy could be increased if margins were not negative.
  • Treatment planning was computerized in 59 centers.
  • The irradiation dose was prescribed at the ICRU point in 56 centers and portal films were made in 54 centers.
  • [MeSH-minor] Adult. Aged. Dose Fractionation. Female. Guideline Adherence. Humans. Intraoperative Period. Italy. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Radiation Oncology. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Adjuvant. Societies, Medical. Surveys and Questionnaires. Time Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705400.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Investigator] Bagnoli R; Roncadin M; Necchia R; Iannone T; D'Affronto C; Moro G; Brandoli V; Baldissera A; Granellini M; Baroncelli G; Giuliano G; Amichetti M; Tagliagambe A; Palmucci T; Tafuri G; Mazzei E; Cefaro GA; Valli MC; Ziccarelli L; Cafaro I; Guenzi M; Pecci AP; La Porta MC; Arcangeli G; Calmieri L; Leopardi F; Mignona M; Pietta N; De Renzis C; Leonardi C; Valdagni R; Lombardi F; Falchi AM; Meregalli S; Morra A; Gamba G; Sotti G; Evangelista G; Martinelli R; Francolini DC; Perrucci E; Piva D; Moda S; Chiavacci A; Emiliani E; Venturini A; Zini G; Fusco V; Bonanni A; Donato V; Banelli E; Nardone L; Orsatti M; Dedola MF; Siccardi C; Di Lorenzo I; Chirico L; Gribaudo S; Rovea P; Mussari S; Coghetto F; Beorchia A; Buffoli A; Guglielmi R; Gabbani M; Rosetto ME
  •  go-up   go-down


3. Asami S, Idani H, Kubo S, Sasaki H, Kurose Y, Nojima H, Yoshioka T, Muro M, Kumano K, Hirata M, Yamashita T, Kin H, Takakura N: [A case of gastric cancer with peritoneal dissemination which has been alive more than three years responding to intraperitoneal chemotherapy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2287-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of gastric cancer with peritoneal dissemination which has been alive more than three years responding to intraperitoneal chemotherapy].
  • Three courses of neoadjuvant chemotherapy combined with S-1 and CDDP were performed.
  • This chemotherapy showed a substantial reduction of the size of primary tumor and peritoneal dissemination by CT examination.
  • Surgical resection consisted of distal gasterectomy and D2 lymph node dissection was performed, and an ip catheter was placed through the douglas pouch, and the catheter was attached to the subcutaneous portal delivery system for ip chemotherapy.
  • Operative cytology of ascites proved positive and remnant neoplasm cells were identified in the peritoneum.
  • However, we continued the ip chemotherapy for twenty-five times on ambulant basis.
  • Most gastric cancer patients with peritoneal dissemination die within a few months, and there is no standard treatment for peritoneal dissemination from gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Peritoneal Neoplasms / secondary. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Cisplatin / administration & dosage. Drug Combinations. Gastrectomy. Humans. Infusions, Parenteral. Lymph Node Excision. Male. Middle Aged. Neoadjuvant Therapy. Oxonic Acid / administration & dosage. Paclitaxel / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037398.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Ionescu M, Dumitraşcu T, Stroescu C: [Liver resection after downstaging with systemic chemotherapy in a case of a multicentric hepatocellular carcinoma with virus B cirrhosis]. Chirurgia (Bucur); 2007 May-Jun;102(3):337-43
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver resection after downstaging with systemic chemotherapy in a case of a multicentric hepatocellular carcinoma with virus B cirrhosis].
  • We report the case of a 27 years old woman with multicentric hepatocellular carcinoma and virus B cirrhosis, portal vein thrombosis with systemic chemotherapy followed be hepatic resection--left hepatectomy and lymph node dissection for the remaining tumor.
  • Postoperative outcome was uneventful, the patient being alive at 22 month after diagnosis, without recurrence.
  • Combined modalities with systemic chemotherapy and surgical resection can achieve complete clinical remission and long-term control of disease in patients with unresectable hepatocarcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / surgery. Hepatectomy. Hepatitis B, Chronic / diagnosis. Liver Cirrhosis / diagnosis. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17687865.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


5. Asakura H, Ohtsuka M, Ito H, Kimura F, Ambiru S, Shimizu H, Togawa A, Yoshidome H, Kato A, Miyazaki M: Long-term survival after extended surgical resection of intrahepatic cholangiocarcinoma with extensive lymph node metastasis. Hepatogastroenterology; 2005 May-Jun;52(63):722-4
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after extended surgical resection of intrahepatic cholangiocarcinoma with extensive lymph node metastasis.
  • We present a case of long-term survival in a patient that involved intrahepatic cholangiocarcinoma that metastasized to the paraaortic lymph nodes.
  • A 62-year-old man underwent extended left hepatic lobectomy with caudate lobe resection, extrahepatic bile duct resection, portal vein resection and reconstruction, and middle hepatic vein resection and reconstruction with lymph node dissection for a liver tumor that was located in the caudate lobe.
  • Histological examination of the resected specimen revealed moderately differentiated adenocarcinoma compatible with cholangiocarcinoma, and lymph node metastases were found in the area of the hepatoduodenal ligament and the paraaortic region.
  • After surgical resection, recurrence was detected twice in the lymph nodes at the site of the left supraclavicular region.
  • These recurrent tumors were completely eliminated by systemic chemotherapy with cisplatin or mitomycin C.
  • The patient is now doing well 6 years and 5 months after surgical treatment.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Cholangiocarcinoma / surgery. Hepatectomy. Lymph Node Excision. Lymphatic Metastasis / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Disease-Free Survival. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Retreatment

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966191.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


6. Tamesa T, Mori N, Okada T, Takemoto N, Sakamoto K, Yamasaki T, Tangoku A, Oka M: [A case of Vp4 hepatocellular carcinoma treated with surgical resection and continuous intrahepatic artery infusion chemotherapy of low-dose cisplatin and 5-fluorouracil]. Gan To Kagaku Ryoho; 2003 Oct;30(11):1769-72
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of Vp4 hepatocellular carcinoma treated with surgical resection and continuous intrahepatic artery infusion chemotherapy of low-dose cisplatin and 5-fluorouracil].
  • Portal venous thrombus was observed from the right portal branch to left portal branch and superior mesenteric vein.
  • An extended right hemihepatectomy with extraction of portal venous thrombus was performed.
  • After chemotherapy, one intrahepatic metastasis appeared and RFA was performed for this tumor.
  • At 16 months after surgery, she had multiple lymph node metastases and died at 20 months after the surgery without intrahepatic metastasis.
  • Low-dose CDDP/5-FU intra-hepatic artery infusion chemotherapy was effective for prevention of intrahepatic recurrence after resection of HCC with portal venous thrombus.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Hepatectomy. Liver Neoplasms / drug therapy. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Cisplatin / administration & dosage. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Hepatic Artery. Humans. Infusions, Intra-Arterial / methods. Middle Aged. Neoplastic Cells, Circulating / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14619515.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


7. Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Ohge H, Sueda T: Postoperative adjuvant chemotherapy improves survival after surgical resection for pancreatic carcinoma. J Gastrointest Surg; 2008 Mar;12(3):534-41
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative adjuvant chemotherapy improves survival after surgical resection for pancreatic carcinoma.
  • Pancreatic carcinoma is one of the most aggressive types of gastrointestinal malignancy, and its prognosis remains extremely dismal.
  • Overall 1-, 2-, and 5-year survival rates were 59, 28, and 7%, respectively (median survival time, 12.1 months).
  • Univariate analysis revealed that postoperative adjuvant chemotherapy, portal vein invasion, lymph node metastasis, extrapancreatic nerve plexus invasion, surgical margin status, UICC pT factor, and UICC stage were significantly associated with long-term survival (P<0.01).
  • Furthermore, use of postoperative adjuvant chemotherapy and absence of extrapancreatic nerve plexus invasion were found to be significant independent predictors of a favorable prognosis using a Cox proportional hazard regression model (P<0.05).
  • These results suggest that postoperative adjuvant chemotherapy may improve survival after surgical resection for pancreatic carcinoma and that extrapancreatic nerve plexus invasion indicates a poor prognosis for long-term survival.
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / therapeutic use. Chemotherapy, Adjuvant. Female. Fluorouracil / therapeutic use. Humans. Injections, Intra-Arterial. Male. Neoplasm Invasiveness. Postoperative Period. Proportional Hazards Models. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2003 Mar;27(3):324-9 [12607060.001]
  • [Cites] J Am Coll Surg. 1996 Aug;183(2):164-84 [8696550.001]
  • [Cites] J Gastrointest Surg. 2007 Mar;11(3):338-44 [17458608.001]
  • [Cites] Langenbecks Arch Surg. 2000 Jan;385(1):14-20 [10664114.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):508-17 [9790340.001]
  • [Cites] Ann Surg Oncol. 2004 Jul;11(7):644-9 [15197014.001]
  • [Cites] Surgery. 2006 Sep;140(3):448-53 [16934608.001]
  • [Cites] J Gastrointest Surg. 2006 Nov;10(9):1199-210; discussion 1210-1 [17114007.001]
  • [Cites] Dig Surg. 2000;17(1):29-35 [10720829.001]
  • [Cites] Abdom Imaging. 2006 Sep-Oct;31(5):568-74 [16465578.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Am J Surg. 2005 Mar;189(3):278-82 [15792750.001]
  • [Cites] J Surg Oncol. 2000 May;74(1):36-40 [10861607.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1685-95 [12365016.001]
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] Surgery. 1995 Jun;117(6):616-23 [7778025.001]
  • [Cites] Surgery. 2005 Oct;138(4):618-28; discussion 628-30 [16269290.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(4):549-58 [14962722.001]
  • [Cites] Pancreas. 2006 Jan;32(1):37-43 [16340742.001]
  • [Cites] Ann Surg. 1999 May;229(5):613-22; discussion 622-4 [10235519.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1372-81 [15812554.001]
  • [Cites] Jpn J Clin Oncol. 2006 Mar;36(3):159-65 [16490736.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Mar;59(4):447-54 [16855842.001]
  • [Cites] Oncology. 2005;68(2-3):171-8 [16006754.001]
  • [Cites] Surgery. 1973 Feb;73(2):307-20 [4265314.001]
  • [Cites] Surgery. 2005 Nov;138(5):962-3 [16291404.001]
  • [Cites] J Surg Oncol. 2006 May 1;93(6):485-90 [16615151.001]
  • [Cites] J Surg Oncol. 1997 Jul;65(3):164-70 [9236924.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Ann Surg Oncol. 2006 Feb;13(2):150-8 [16418882.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]
  • [Cites] Br J Cancer. 2005 Jan 17;92(1):21-3 [15597096.001]
  • [Cites] Pancreas. 1996 May;12(4):357-61 [8740402.001]
  • [Cites] Eur J Cancer. 1993;29A(5):698-703 [8471327.001]
  • [Cites] Pancreas. 2005 Jul;31(1):69-73 [15968250.001]
  • [Cites] Surg Clin North Am. 2001 Jun;81(3):595-610 [11459274.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):930-5 [1735083.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1575-9 [16721372.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Pancreas. 2003 Apr;26(3):243-9 [12657950.001]
  • [Cites] Surg Endosc. 2006 Apr;20 Suppl 2:S446-9 [16557419.001]
  • [Cites] Surgery. 2006 Mar;139(3):288-95 [16546491.001]
  • (PMID = 18026816.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Wanebo HJ, Glicksman AS, Vezeridis MP, Clark J, Tibbetts L, Koness RJ, Levy A: Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Arch Surg; 2000 Jan;135(1):81-7; discussion 88
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer.
  • HYPOTHESIS: Neoadjuvant therapy has the potential to induce regression of high-risk, locally advanced cancers and render them resectable.
  • Preoperative chemoradiotherapy is proposed as a testable treatment concept for locally advanced pancreatic cancer.
  • A course of chemotherapy with fluorouracil and cisplatin plus radiotherapy was then initiated.
  • Reexploration and resection were planned subsequent to neoadjuvant therapy.
  • INTERVENTIONS: Surgically staged patients with locally advanced pancreatic cancer were treated by preoperative chemotherapy with bolus fluorouracil, 400 mg/m2, on days 1 through 3 and 28 through 30 accompanied by a 3-day infusion of cisplatin, 25 mg m2, on days 1 through 3 and 28 through 30 and concurrent radiotherapy, 45 Gy.
  • RESULTS: Of 14 patients who enrolled in the protocol and were initially surgically explored, 3 refused the second operation and 11 were reexplored; 2 showed progressive disease and were unresectable and 9 (81%) had definitive resection.
  • Pancreatic resection included standard Whipple resection in 1 patient, resection of body and neck in 1 patient, and extended resection in 6 patients (portal vein resection in 6, arterial resection in 4).
  • One patient who was considered too frail for resection had core biopsies of the pancreatic head, node dissection, and an interstitial implant of the tumorous head.
  • Lymph node downstaging occurred in 2 of 4 patients who had positive peripancreatic nodes at the initial surgical staging.
  • In the definitive surgery group the median survival was 19 months after beginning chemoradiotherapy and 16 months after definitive surgery.
  • The absolute 5-year survival was 11% of 9 patients, 1 is surviving 96 months (with no evidence of disease) after chemoradiotherapy and extended pancreatic resection including resection of the superior mesenteric artery and the portal vein for stage III cancer.
  • [MeSH-major] Neoadjuvant Therapy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pancreas / pathology. Radiotherapy Dosage. Reoperation. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10636353.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


9. Roa I, de Aretxabala X, Araya JC, Villaseca M, Roa J, Burgos L, Guzmán P: [Findings in surgical reinterventions for cancer of the gallbladder in patients with and without preoperative chemotherapy and radiotherapy]. Rev Med Chil; 2001 Sep;129(9):1013-20
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Findings in surgical reinterventions for cancer of the gallbladder in patients with and without preoperative chemotherapy and radiotherapy].
  • BACKGROUND: The usefulness of surgery in the treatment of gallbladder cancer has not been clearly established.
  • PATIENTS AND METHODS: We report 54 patients with gallbladder cancer that were subjected to a second surgical intervention for resection of liver segments IVb and V and lymph nodes corresponding to the liver hilar, portal, peripancreatic, celiac artery and periaortic territories.
  • Thirteen of these patients were subjected to preoperative chemo-radiotherapy (4500 Gy and 5-fluouracil 500 mg/m2).
  • RESULTS: Lymph node metastases were found in 25 and 38%, and liver metastases in 25 and 28% of patients with or without chemo-radiotherapy respectively.
  • Lymph nodes were atrophic in 67% of cases and had foci of cortical necrosis in 46% of cases.
  • Three cases had regional lymph node and liver metastases.
  • CONCLUSIONS: No differences in the number of lymph node or liver metastases were observed between patients with and without chemo-radiotherapy.
  • No effect of the treatment on residual tumor was observed either.
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Necrosis. Neoplasm Invasiveness. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Rev Med Chil. 2001 Sep;129(9):979-81 [11725477.001]
  • (PMID = 11725464.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Chile
  •  go-up   go-down


10. Kurahara H, Shinchi H, Maemura K, Mataki Y, Aoki M, Sakoda M, Ueno S, Natsugoe S, Takao S: [A case of curatively resected locally advanced pancreatic cancer after chemoradiation therapy]. Gan To Kagaku Ryoho; 2010 Oct;37(10):1983-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of curatively resected locally advanced pancreatic cancer after chemoradiation therapy].
  • A 68-year-old man admitted for pancreatic tumor detected by US was found by computed tomography(CT)to have locally advanced pancreatic cancer invading the portal vein and neural plexus of the superior mesenteric artery without distant metastasis.
  • We conducted preoperative chemoradiation therapy containing S-1 and hyperfractionated accelerated radiation therapy (50 Gy).
  • Reevaluation of CT after chemoradiation therapy showed that the primary tumor reduced 52% without distant metastasis.
  • Based on these findings, we conducted subtotal stomach-preserving pancreaticoduodenectomy with portal vein resection.
  • The portal vein was surrounded with extensive fibrosis and free from cancer cells.
  • Extrapancreatic nerve plexus invasion and lymph node metastasis were not observed.
  • The postoperative course was uneventful, and adjuvant chemotherapy (S-1) was started.
  • [MeSH-minor] Aged. Combined Modality Therapy. Drug Combinations. Humans. Male. Neoplasm Staging. Oxonic Acid / therapeutic use. Tegafur / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20948269.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


11. Zhao DB, Gao JD, Shan Y, Zhou ZX, Yuan XH, Wu JX, Shao YF: [Characteristics of metastasis and recurrence following curative resection for colonic carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Jul;9(4):291-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gross classification,histological type, differentiation, lymph node metastasis were correlated with metastasis/recurrence.
  • Univariate analysis revealed that gross classification, histological type, differentiation, lymph node metastasis, blood vessel invasion, TNM Stage, postoperative chemotherapy, portal chemotherapy were prognostic factors.
  • Cox regression analysis revealed that only gross classification, lymph node metastasis, postoperative chemotherapy, portal chemotherapy were independent prognostic factors.
  • Gross classification, lymph node metastasis, postoperative chemotherapy, and portal chemotherapy are independent prognostic factors.
  • [MeSH-major] Colonic Neoplasms / pathology. Lymphatic Metastasis / diagnosis. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Period. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886105.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


12. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K: Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas; 2004 Apr;28(3):219-30
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Preoperative histologic diagnosis and diagnostic imaging are fundamentals in managing the disease, but it is not rare to find unexpected peritoneal dissemination or liver metastasis at the time of operation.
  • Resecting the portal vein and peripancreatic plexus were performed on 40% of the patients who underwent pancreatectomy for invasive cancer in the head of the pancreas.
  • Radical lymph node dissection, or combined resection of the large vessels, did not seem to improve survival further than the standard resection.
  • Multidisciplinary treatments combined with surgery were performed, and various effects of postoperative chemotherapy after pancreatectomy, intraoperative- and postoperative-radiation therapy, or postoperative chemotherapy for unresectable tumor, were shown.
  • Development of unconventional therapies and refinement of the conventional therapy should be promoted on a randomized prospective trial basis.
  • To promote this effort, which requires the international comparisons and cooperation, JPS developed a computerized JPS registration system downloadable from the JPS website (http://www.kojin.or.jp/suizou/index.html).
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy. Registries
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Combined Modality Therapy. Female. Humans. Japan. Lymph Node Excision. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pancreatectomy. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15084961.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Tsuchiya T, Hiramatsu K, Tanaka H, Machiki Y, Sakuragawa T, Otsuji H, Hara T, Kimura A, Yoshida K, Hosoya J, Kojima T, Kato K: [A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases]. Gan To Kagaku Ryoho; 2009 Dec;36(13):2641-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases].
  • A case of gastric endocrine cell carcinoma successfully treated by FU (5-FU/UFT) +irinotecan (CPT-11) adjuvant therapy against recurrent metastases is reported with some discussion.
  • Total gastrectomy with pancreato-splenectomy with D2 lymph node dissection was done for curative resection.
  • The pathological diagnosis was gastric endocrine cell carcinoma because Grimelius and Chromogranin A stained positive histologically.
  • Seven months after operation, recurrent liver metastases with tumor embolism of the portal vein were revealed by enhanced CT examination.
  • FU (5-FU/UFT) +CPT-11 was done as the first-line adjuvant chemotherapy.
  • Metastatic lesion of the liver and portal vein tumor embolism was decreased.
  • This therapy was evaluated as a partial response (PR) in twelve months and the patient died three years and eight months after operation.
  • Based on this finding, we recommend adjuvant chemotherapy by FU+CPT-11 for gastric endocrine cell carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Chemotherapy, Adjuvant. Fluorouracil / administration & dosage. Gastrectomy. Humans. Lymph Node Excision. Male. Neoplasm Metastasis. Tegafur / administration & dosage. Uracil / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009471.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


14. Junginger T, Kneist W, Seifert JK: [Surgical treatment of colorectal liver metastases]. Zentralbl Chir; 2003 Nov;128(11):911-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of colorectal liver metastases].
  • [Transliterated title] Chirurgische Therapie von Lebermetastasen kolorektaler Karzinome.
  • Resection is the only curative treatment of colorectal liver metastases proofed by a long-term follow-up.
  • The resection is not indicated in cases with non resectable extrahepatic tumours and lymph node metastases distal the hepatoduodenal ligament.
  • Aims of new concepts of operative therapy are the improvement of resectability by preoperative portal vein embolization, the resection combined with local destructive methods and preoperative chemotherapy.
  • Additionally, new drugs for adjuvant treatment after resection of metastases are studied.
  • The interdisciplinary discussion of the course before and after therapy is essential for the individual optimal treatment.
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Hepatectomy. Humans. Liver Cirrhosis / complications. Lymphatic Metastasis / radiography. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Patient Selection. Postoperative Complications. Prognosis. Prospective Studies. Randomized Controlled Trials as Topic. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14669111.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 72
  •  go-up   go-down


15. Welsch T, Büchler MW, Schmidt J: [Surgery for pancreatic cancer]. Z Gastroenterol; 2008 Dec;46(12):1393-403
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Chirurgie des Pankreaskarzinoms.
  • Even after complete resection and adjuvant chemotherapy, the 5-year survival rate amounts to merely 20 - 25%.
  • Besides a high resistance to chemotherapy and early lympho- and haematogenic metastases, the reason for this is often tumour extension beyond the medial and dorsal resection margins.
  • Although infiltration of the portal vein is not a contraindication for curative resection with vascular reconstruction which gives comparable survival rates, a radical, extended lymphadenectomy does not seem reasonable on the basis the available data.
  • An R0 resection and tumour-free lymph nodes (N0 stage) are the two factors that can provide the best prognosis for the patient with a median survival of 2 years and a good quality of life.
  • In order to achieve a further and urgently needed improvement in treatment results, one should consider, if possible, all suitable patients for enrolment in current clinical studies on neoadjuvant, surgical, or adjuvant therapy.
  • [MeSH-minor] Humans. Lymph Node Excision. Neoplasm Invasiveness / pathology. Neoplasm Staging. Pancreaticoduodenectomy / methods. Prognosis. Splenectomy / methods. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19053009.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 101
  •  go-up   go-down


16. Baulieux J, Delpero JR: [Surgical treatment of pancreatic cancer: curative resections]. Ann Chir; 2000 Sep;125(7):609-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of pancreatic cancer: curative resections].
  • [Transliterated title] Traitement chirurgical du cancer du pancréas: les exérèses à visée curative.
  • Lymph node and/or vascular involvement and retroperitoneal tissue invasion constitute very poor prognostic factors; however, lymph node involvement limited to the first draining nodes and limited invasion of the mesenteric-portal vein do not constitute contraindications to surgical resection.
  • Cephalic pancreaticoduodenectomy is still the reference procedure and its postoperative mortality has greatly decreased.
  • Concomitant or neoadjuvant chemotherapy-radiotherapy, currently under evaluation, may increase resection and survival rates.
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Postoperative Complications. Prognosis. Radiotherapy, Adjuvant. Survival Analysis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11051689.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] FRANCE
  • [Number-of-references] 54
  •  go-up   go-down


17. Carpizo DR, Are C, Jarnagin W, Dematteo R, Fong Y, Gönen M, Blumgart L, D'Angelica M: Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center. Ann Surg Oncol; 2009 Aug;16(8):2138-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the patients with EHD, multivariate analysis identified higher clinical risk score, incomplete resection of all EHD, EHD detected intraoperatively, and having received neoadjuvant chemotherapy to be independently associated with a worse survival.
  • Patients with portal lymph node metastases had worse survival than those with lung or ovarian metastases.
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Prognosis. Prospective Studies. Retrospective Studies. Survival Rate. Treatment Outcome


18. Li FH, Chen XQ, Luo HY, Li YH, Wang F, Qiu MZ, Teng KY, Li ZH, Xu RH: [Prognosis of 84 intrahepatic cholangiocarcinoma patients]. Ai Zheng; 2009 May;28(5):528-32
Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Current treatment for ICC is unsatisfied.
  • For the patients with resectable ICC, univariate analysis revealed that operation pattern, histological type, tumor size and number, lymph node metastasis, intrahepatic metastasis, portal vein thrombus, postoperative serum level of albumin, preoperative serum levels of CEA, CA199, TBIL, ALT and AST were related to the prognosis; multivariate analysis found that operation pattern, histological type, tumor number, preoperative serum levels of CEA, CA199 and TBIL were independent prognostic factors.
  • For the patients with unresectable ICC, univariate analysis found that histological type and preoperative serum level of CA199 were related to the prognosis; whereas multivariate analysis found that histological type was the only independent prognostic factor.
  • Chemotherapy showed no survival benefit in both resectable and unresectable ICC groups (P=0.30, P=0.78).
  • CONCLUSIONS: Radical resection is the main effective treatment for ICC patients to achieve long-term survival.
  • [MeSH-minor] Adult. Aged. Bile Duct Neoplasms / blood. Bile Duct Neoplasms / pathology. Bile Duct Neoplasms / surgery. Bilirubin / blood. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Chemotherapy, Adjuvant. Cholangiocarcinoma / blood. Cholangiocarcinoma / pathology. Cholangiocarcinoma / surgery. Female. Follow-Up Studies. Humans. Liver Neoplasms / blood. Liver Neoplasms / pathology. Liver Neoplasms / surgery. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Neoplastic Cells, Circulating. Palliative Care. Proportional Hazards Models. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19624884.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


19. Suzuki S, Sakaguchi T, Yokoi Y, Okamoto K, Kurachi K, Tsuchiya Y, Okumura T, Konno H, Baba S, Nakamura S: Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma. World J Surg; 2002 Jun;26(6):687-93
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma.
  • The clinicopathological characteristics relevant to prognosis after surgical treatment of intrahepatic cholangiocarcinoma (ICC) remain unclear.
  • Resection of the extrahepatic bile duct was performed in 14 patients, and reconstruction of the portal vein was accomplished in 5 patients.
  • Stage IVA or IVB tumors were seen in 13 patients, and lymph node (LN) metastasis was present in 14 patients.
  • The estimated 5-year survival rate after surgery for mass-forming ICC was 28%, with median survival time of 18 months.
  • These variables include mass-forming ICC with periductal infiltration, perineural invasion, portal vein invasion, presence of intrahepatic metastasis, and two or more LN metastases.
  • Because the presence of intrahepatic metastasis was closely related to a poor prognosis in patients with mass-forming ICC, efficacious chemotherapy would be needed to control development of the lesion.
  • [MeSH-minor] Aged. Female. Hepatectomy / methods. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis. Survivors

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1996 Nov;83(11):1517-21 [9014664.001]
  • [Cites] Cancer. 1989 Dec 1;64(11):2226-32 [2553242.001]
  • [Cites] Surgery. 1992 Jun;111(6):617-22 [1317612.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):83-8 [7740815.001]
  • [Cites] Ann Surg. 1996 Oct;224(4):463-73; discussion 473-5 [8857851.001]
  • [Cites] Ann Surg. 1992 Apr;215(4):344-9 [1558415.001]
  • [Cites] Br J Surg. 1998 Sep;85(9):1206-9 [9752860.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(2):142-8 [10398901.001]
  • [Cites] Eur J Surg Oncol. 1996 Apr;22(2):186-8 [8608839.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(1):41-7 [9683753.001]
  • [Cites] Ann Surg. 1998 Jan;227(1):70-9 [9445113.001]
  • [Cites] Hum Pathol. 1988 Oct;19(10):1228-34 [2844646.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(2):108-16 [10398896.001]
  • [Cites] Cancer. 1977 Jan;39(1):232-46 [64293.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(2):122-7 [10398898.001]
  • [Cites] Hepatogastroenterology. 1990 Apr;37(2):176-81 [2160420.001]
  • [Cites] HPB Surg. 1992;5(2):95-101; discussion 101-2 [1319194.001]
  • [Cites] J Gastroenterol Hepatol. 1994 Sep-Oct;9(5):442-6 [7827293.001]
  • [Cites] Cancer. 1998 Nov 1;83(9):1923-9 [9806650.001]
  • [Cites] Ann Surg. 1990 Mar;211(3):277-87 [2155591.001]
  • [Cites] J Surg Oncol. 1995 May;59(1):40-4 [7745976.001]
  • [Cites] Cancer. 1995 Dec 15;76(12):2449-56 [8625070.001]
  • [Cites] Arch Surg. 1995 Oct;130(10):1073-8 [7575119.001]
  • (PMID = 12053220.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Dörffel Y, Wermke W: Neuroendocrine tumors: characterization with contrast-enhanced ultrasonography. Ultraschall Med; 2008 Oct;29(5):506-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ), portal venous (25-120 sec p.i.
  • Necrotic areas (25/83) were detected after interferon therapy, embolization, systemic chemotherapy, and radiofrequency ablation of liver metastases, but did not develop after somatostatin receptor radionuclide therapy.
  • The hypervascularized tissue was found in the primary lesions, in liver, lymph node metastases and any kind of abdominal metastases.
  • In most cases real-time CEUS may replace other imaging techniques.
  • [MeSH-minor] Adult. Carcinoid Tumor / pathology. Carcinoid Tumor / ultrasonography. Humans. Jejunal Neoplasms / secondary. Jejunal Neoplasms / ultrasonography. Liver Neoplasms / secondary. Liver Neoplasms / ultrasonography. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Metastasis / ultrasonography. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / ultrasonography. Sensitivity and Specificity. Ultrasonography / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241507.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


21. Caudry M, Ratoanina JL, Escarmant P, Maire JP: [Target volume in radiotherapy of gastric adenocarcinoma]. Cancer Radiother; 2001 Oct;5(5):523-33
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Les volumes-cibles de la radiothérapie des adénocarcinomes gastriques.
  • A GTV should be considered in preoperative or exclusive radiation therapy.
  • Therefore this volume will include: the tumor and the remaining stomach or their "bed of resection", a part of the transverse colon, the duodenum, the pancreas and the truncus of the portal vein.
  • (1) contiguous microscopic extension from deeply invasive T3 and T4 tumors, that remain amenable to local sterilization with doses of 45-50 Gy, delivered in a CTV including the peritoneal cavity at the level of the gastric bed, and under the parietal incision;.
  • (2) true "peritoneal carcinomatosis", with widespread seeds, where chemotherapy (systemic or intraperitoneal) is more appropriate.
  • c) A lymphatic volume including the lymph node groups 1 to 16 of the Japanese classification.
  • In distal and proximal tumors, involvement of resection margins is of poor prognosis--a radiation boost must be delivered at this level.
  • In tumors invading the distal esophagus, a more complete coverage of mediastinal lymph nodes should be considered, especially in patients in good general condition.
  • In contrast, for distal tumors, the hepatic pedicle and the hepatoduodenal ligament should be included whereas the splenic area could be spared.
  • CONCLUSION: Planning the treatment of gastric cancer remains difficult; target volumes must be customized by experienced radiation oncologists according to tumoral and clinical situation.
  • [MeSH-minor] Dose Fractionation. Humans. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm, Residual

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11715304.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 65
  •  go-up   go-down






Advertisement